作者: Susan M. Galbraith , Ross J. Maxwell , Martin A. Lodge , Gillian M. Tozer , John Wilson
关键词: Combretastatin A-4 phosphate 、 Medicine 、 Vascular permeability 、 Nuclear medicine 、 Vascular-targeting agent 、 Kidney 、 Chemotherapy 、 ZD6126 、 Blood flow 、 Magnetic resonance imaging
摘要: Purpose: Combretastatin A4 phosphate (CA4P) is a novel vascular targeting agent. Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) studies were performed to examine changes in parameters related blood flow and permeability tumor normal tissue after CA4P treatment. Materials Methods: Changes kinetic DCE-MRI (transfer constant [Ktrans] area under medium-time curve [AUC]) over 24 hours treatment with measured 18 patients phase I trial compared those obtained the rat P22 carcinosarcoma model, using same technique. Rats treated 30 mg/kg of CA4P; received escalating doses from 5 114 mg/m2. Results: A similar pattern time course change was seen rats humans. Rat Ktrans reduced by 64% 6 (30 mg/kg). No significant reductions kidney or muscle seen. Significant wer...